Post on 30-Jun-2018
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 1
Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245709) in Tumor Models with Diverse Genetic Alterations Impacting the PI3K Pathway Peiwen Yu, A. Douglas Laird, Xiangnan Du, Jianming Wu, Kwang-Ai Won, Kyoko Yamaguchi, Pin Pin Hsu, Fawn Qian, Christopher T. Jaeger, Wentao Zhang, Chris A. Buhr, Paula Shen, Wendy Abulafia, Jason Chen, Jenny Young, Arthur Plonowski, F. Michael Yakes, Felix Chu, Michelle Lee, Frauke Bentzien, Sanh Tan Lam, Stephanie Dale, David J. Matthews, Peter Lamb, Paul Foster Exelixis, Inc., South San Francisco, CA 94080 Running Title: Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) Key words: XL765, SAR245409, PI3K, mTOR, inhibitor Corresponding author: A. Douglas Laird, Ph.D. Executive Director, Translational Medicine Exelixis 210 East Grand Ave South San Francisco, CA 94080 Ph: 650 837 7485 Fax: 650 837 7410 dlaird@exelixis.com Financial support/Conflict of interest statement: The authors are all current or former employees of Exelixis, Inc. Word count (excluding references): 8926 Total number of figures: 4 (+ 5 supplemental, including 2 added to address reviewer comments) Total number of tables: 3 (+ 3 supplemental, including one added to address reviewer comments)
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 2
Abstract Activation of the PI3K pathway is a frequent occurrence in human tumors and is thought
to promote, growth, survival and resistance to diverse therapies. Here we report
pharmacological characterization of the pyridopyrimidinone derivative, XL765
(SAR245409), a potent and highly selective pan inhibitor of Class I PI3Ks (α, β, γ, and δ)
with activity against mTOR. Broad kinase selectivity profiling of >130 protein kinases
revealed that XL765 is highly selective for Class I PI3Ks and mTOR over other kinases.
In cellular assays, XL765 inhibits the formation of PIP3 in the membrane, and inhibits
phosphorylation of AKT, p70S6K and S6 phosphorylation in multiple tumor cell lines
with different genetic alterations impacting the PI3K pathway. In a panel of tumor cell
lines, XL765 inhibits proliferation with a wide range of potencies, with evidence of an
impact of genotype on sensitivity. In mouse xenograft models, oral administration of
XL765 results in dose-dependent inhibition of phosphorylation of AKT, p70S6K, and S6
with a duration of action of approximately 24 h. Repeat dose administration of XL765
results in significant tumor growth inhibition in multiple human xenograft models in nude
mice that is associated with anti-proliferative, anti-angiogenic, and pro-apoptotic effects.
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 3
Introduction Class I PI3 kinases convert phosphatidylinositol 4,5-bisphosphate (PIP2) to
phosphatidylinositol 3,4,5-trisphosphate (PIP3) in response to external cell stimuli (1, 2).
Activation of Class IA PI3Ks (PI3Kα, -β, and -δ) is mediated by RTKs. G-protein–
coupled hormone receptors are implicated in activation of PI3Kβ and Class IB PI3K
(PI3Kγ) (3). Ras, another important mediator of extracellular stimuli, can also promote
PI3K activation, and PI3K can mediate cellular transformation by Ras (4). Downstream
effectors of PI3K signaling, such as phosphoinositide-dependent kinase-1 (PDK1) and
AKT, bind to PIP3 at the cell membrane and are subsequently activated by
phosphorylation (1). In turn, PDK1 and AKT activate growth pathways, inhibit apoptotic
signaling and regulate transition through restriction points in the cell cycle via
phosphorylation of their respective substrates (1).
mTOR is the kinase component of two multi-subunit complexes called mTORC1
(includes mTOR/Raptor) and mTORC2 (includes mTOR/Rictor) (5,6). mTORC1 is
activated via PI3K pathway signaling and also via PI3K-independent mechanisms
involving sensing of cellular amino acid levels, AMP levels, and hypoxia, and drives
cellular growth by regulating protein translation and degradation (5,6). mTORC2 is
activated via growth factor-dependent signaling via mechanism(s)that are still being
elucidated, and regulates cell growth, proliferation, and survival via phosphorylation of
the AKT kinase (5, 6, 7).
Dysregulation of PI3K pathway components, resulting in hyperactivated PI3K and/or
mTORC1 signaling, is observed in various cancers and correlates with tumor growth and
survival (1). For example, the catalytic subunit of PI3Kα (p110α), encoded by the
PIK3CA gene, is mutated in 12% of human cancers (8). This is likely an underestimate
since many of these data are presumably generated by hot-spot sequencing. In addition,
the tumor suppressor PTEN, which serves as a critical negative regulator of PI3K
signaling by converting PIP3 back to PIP2, is frequently deleted or downregulated in
human tumors (1,9). Moreover, the tumor suppressor gene LKB-1 which negatively
regulates mTORC1 is mutated/inactivated in a variety of familial and sporadic tumors
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 4
(10). PI3K pathway signaling is implicated in tumor cell invasion, migration and
dissemination (11). Genetic and pharmacologic approaches have demonstrated that PI3K
signaling mediates vascular endothelial growth factor (VEGF) production,
neoangiogenesis, vascular permeability, and vessel integrity in preclinical tumor models
(12,13,14).
Resistance to a variety of anticancer therapies, including receptor tyrosine kinase (RTK)
inhibitors and genotoxic agents, has been attributed to ongoing activation of the PI3K/
PTEN pathway (15, 16, 17). PI3K pathway inhibitors have been shown to sensitize
cancer cells to agents targeting HER2, MET and EGFR as well as platinum drugs and
taxanes (18, 19, 20, 21, 22, 23).
mTOR has been extensively explored as an oncology target (24). The macrolide
antibiotic rapamycin is a potent inhibitor of the mTORC1 complex. Several analogs of
rapamycin have been tested clinically in various oncology indications, and evidence of
therapeutic benefit has been observed (24). For example, the FDA has approved
TORISEL™ (temsirolimus; Pfizer) for patients with advanced renal cell carcinoma
(RCC) and Afinitor™ (everolimus; Novartis) for the treatment of patients with advanced
RCC after failure of treatment with sunitinib or sorafenib, and for advanced ER-positive
breast cancer after failure of treatment with a nonsteroidal aromatase inhibitor. However,
the efficacy of these agents may be limited by the fact that rapamycin analogs do not
inhibit mTORC2 (7). In addition, mTORC1 inhibition may enhance cell survival by
upregulating PI3K/AKT signaling via inhibition of a mTORC1-dependent negative
feedback loop acting through PI3K (24). Thus, selective inhibitors of PI3K and mTOR
signaling have therapeutic potential as single agents and in combination with other
therapies for a variety of cancer indications and several such agents have entered clinical
testing in recent years (1, 24).
XL765 (SAR245409) is a potent and selective inhibitor of Class I PI3Ks. In addition,
XL765 also inhibits mTOR. In cellular assays, treatment with XL765 inhibits
phosphorylation of proteins downstream of PI3K and mTOR, including AKT and
ribosomal protein S6 (S6RP), in multiple tumor cell lines with diverse molecular
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 5
alterations impacting the PI3K pathway. In a broad panel of tumor cell lines XL765
inhibits proliferation with a wide range of potencies, which appeared to be influenced by
genetic background. Oral administration of XL765 in human xenograft tumor models in
athymic nude mice results in dose-dependent inhibition of PI3K pathway components
with a duration of action of at least 24 hours. As a single agent, XL765 shows significant
tumor growth inhibition in multiple human xenograft models at well-tolerated doses.
Taken together, these data support the ongoing clinical investigation of XL765 for the
treatment of cancer.
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 6
Materials and Methods
In vitro kinase inhibition assays
Kinase activity for PI3K isoforms was measured as the percent of ATP consumed
following the kinase reaction using luciferase-luciferin-coupled chemiluminescence as
previously described (25), with ATP concentrations approximately equal to the Km for
each respective kinase. Kinase reactions were initiated by combining test compounds,
ATP and kinase in a 20 µL volume. PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ (Upstate
Biotechnology) final enzyme concentrations were 0.5 nM, 8 nM, 20 nM, and 2 nM,
respectively. A similar assay format was utilized for DNA-PK (purchased from Promega)
and VPS34 (PIK3C3; prepared at Exelixis as an N-terminal tagged full-length human
fusion protein which was expressed in insect cells (BEVS) and affinity purified using
glutathione sepharose). VPS34 assay buffer contained 20 mM TrisHCl, pH 7.5, 3.5mM
MnCl2, 100 mM NaCl, 1 mM DTT and 0.01% cholamidopropyldimethylammonio
propanesulfonate (CHAPS). 0.5 µL DMSO containing varying concentrations of the test
compound was mixed with 10 µL enzyme solution (2X concentration). Kinase reactions
were initiated by the addition of 10 µL of liver phosphatidylinositol (PI) and ATP
solution (2X concentration). Assay concentrations for VPS34, ATP and PI were 40nM,
1µM, and 5 µM, respectively.
Human tumor cell lines
Cell lines were obtained from American Type Culture Collection in 2001- 2005 and
maintained in culture conditions at 37°C under 5% CO2. PC 3, MCF7, and A549 cells
were maintained in DMEM (Cellgro 10-013-CV) containing 10% FBS (Heat Inactivated,
Cellgro, 35-016-CV), 1% non-essential amino acids (NEAA) (Cellgro, 30-002-CI), and
1% penicillin-streptomycin (Cellgro). U87-MG and MDA-MB-468 cells were maintained
in EMEM-Alpha (Cellgro, 10-022-CV), DMEM/F-12 (Cellgro, 15-090-CV),
respectively, supplemented with 10% FBS, 2 mM L-glutamine, 1% NEAA, and 1%
penicillin-streptomycin. LS174T cells were maintained in MEM (GIBCO, 10370-021)
containing 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1% penicillin
streptomycin. Ramos cells were maintained in RPMI 1640 (Cellgro, 10-040-CV)
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 7
containing 10% FBS (Cellgro) and 1% penicillin-streptomycin (Cellgro). OVCAR 3 cells
were maintained in RPMI 1640 containing 20% FBS and 1% penicillin streptomycin.
Immune-Complex mTOR Kinase-Western Immunoblot Analysis
mTORC1: HEK 293 (ATCC) cells were grown in DMEM (Cellgro) containing 10% FBS
(Cellgro), 1% NEAA (Cellgro), and 1% penicillin-streptomycin (Cellgro), and lysed in
ice-cold lysis buffer containing 40 mM HEPES pH 7.5, 120 mM NaCl, 1 mM EDTA,
10 mM Na pyrophosphate, 10 mM β-glycerophosphate, 50 mM NaF, one tablet of
protease inhibitors (Complete-Mini, EDTA-free, Roche), 0.3% CHAPS, and 1.5 mM
Na3VO4. mTORC1 was incubated with anti-mTOR antibody (N-19, Santa Cruz, sc-
1549) 1.5 h to overnight. The resulting immune-complexes were immobilized on IgG
sepharose (GE Healthcare, 17-0618-01), washed sequentially three times with lysis
buffer, once with wash buffer (50 mM HEPES, pH 7.5, 40 mM NaCl, 2 mM EDTA), and
once with kinase buffer (25 mM HEPES, pH 7.5, 50 mM KCl, 20% glycerol, 10
mM MgCl2, 4 mM MnCl2, 1 mM DTT). The immune-complexes (equivalent to 1x106
cells) were pre-incubated at 30°C with XL765 or 0.1% DMSO for 10 minutes, and then
subjected to kinase reaction for 30 min in a final volume of 20 µl (including 10 µl bed
volume) containing kinase buffer, 25 µM ATP, and l µg 4EBP1 (Exelixis). Kinase
reactions were terminated by addition of 3.3 µl 4x sample buffer (Invitrogen, NP0007)
containing 7% β-mercaptoethanol and analyzed by western immunoblotting.
Nitrocellulose membranes were incubated overnight at 4°C with 1/1000 dilution of rabbit
anti-mTOR (Upstate, 07-231) in 5% non-fat milk containing TBST (TBS/0.1% Tween-
20) or with 1/500 dilution of rabbit anti-p4EBP1 (Cell Signaling Technology [CST],
#9459) in 3% BSA/TBST, followed by incubation for 1 h with a 1/5000 dilution of
secondary immunopure peroxidase conjugated goat anti-rabbit IgG (H+L) (Pierce,
31462) in 5% non-fat milk/TBST. Phospho-4EBP1 and mTOR were detected with Super
Signal West Pico Substrate (Pierce, 34080). The p4EBP1 blot was subsequently stripped
and re-probed with anti-4EBP1 antibody (1/1000, CST#9452) with the total 4EBP1
signal detected as described above. Scans were analyzed using ImageQuant software. The
DMSO control sample was used for normalization, and the IC50 value for XL765 was
determined using XLfit4 software.
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 8
mTORC2: HeLa (ATCC) cells were grown in suspension culture in EX-CELLTM HeLa
media (Sigma, 14591C) and lysed as described above with minor modifications. The
mTORC2 complex was incubated with anti-RICTOR antibody (Exelixis) for 2 h and
immune complexes (equivalent to 1×107 cells) prepared as above with minor
modifications. These were pre-incubated at 37°C with a test compound or 0.6% DMSO
for 5 min, and then subjected to a kinase reaction for 8 min in a final volume of 33 μL
(including 5 μL bed volume) containing kinase buffer, 50 μM ATP, and 0.75 μg AKT1
[full-length human AKT1 with amino-terminal Hi tag was expressed in Sf9 cells using
standard procedures, purified, then dephosphorylated with lambda protein phosphatase
(New England Biolabs, P0753L) prior to repurification and use as substrate]. Kinase
reactions were subsequently terminated and resolved as described above with minor
modifications, then transferred onto PVDF membranes at 50 V for 20 h at 4°C. The
membranes were blocked in 5% non-fat milk in TBST for 1 h and incubated overnight at
4°C with 1/1000 dilution of rabbit anti-pAKT (S473) (CST# 4060) in 3% BSA/TBST.
The membranes were washed 3 times in TBST and incubated for 1 h with a 1/10000
dilution of secondary goat anti-rabbit HRP antibody (CST# 2125) in 5% non-fat
milk/TBST. The IC50 value for XL765 was determined as described above.
PIP3 Mass Balance Assay
PC-3 (ATCC) and MCF7 (ATCC) cells were seeded at 2×106 and 2.5×106 cells,
respectively, onto 10-cm dishes in culture medium and incubated at 37°C, 5% CO2 for
24 h. Growth medium was replaced with serum-free DMEM and cells were incubated for
an additional 3 h. Serial dilutions of test compounds in fresh serum-free medium were
added to the cells in a final concentration of 0.3% DMSO (vehicle) and incubated for
23 min prior to recombinant human EGF stimulation (200 ng/ml, R&D Systems,
236-EG) for 2 min. After treatment, the medium was removed, and cellular material was
precipitated with ice cold 10% TCA and collected by centrifugation. The pellet was
washed with 3 ml of 5% TCA/1 mM EDTA. Neutral lipids were extracted from the pellet
with 3 ml of methanol:chloroform (2:1), and then the acidic lipids were extracted with
2.25 ml of methanol:chloroform:12 N HCl (80:40:1). The organic phase was separated
from the aqueous phase by the addition of 0.75 ml of chloroform and 1.35 ml of
0.1 N HCl followed by centrifugation. The organic phase was then collected into a glass
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 9
tube, dried under nitrogen gas, and resuspended by sonication in a water bath in 120 µl of
the PIP3 mass assay buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, and
1.5% sodium cholate).
Assays were conducted in 96-well plates (Perkin-Elmer, L2251692) by incubating 50 µl
of the lipid extract with 50 µl of sensor complex in detection buffer (10 mM Tris-HCl,
pH 7.2, 150 mM NaCl, 7.5 mM EDTA, 0.1% Tween-20, and 1 mM DTT) at ambient
temperature in the dark for 2 h, and plates were read using an AlphaQuest reader (Perkin-
Elmer). The sensor complex contained 15 µl of 100 nM biotinylated PIP3 (Echelon,
C-39B6), 15 µl of 100 nM GST-tagged GRP1-pleckstrin homology (PH) (Echelon,
G-1200), and 20 µl of a mixture of donor and acceptor AlphaScreen beads (GST
detection kit, Perkin-Elmer, 6760603c). The PIP3 mass present was estimated by
comparison to standard curves constructed by addition of known amounts of
diC8 PI(3,4,5)P3 standard (Echelon, P-3908) to the sensor complex.
pAKT and pS6 ELISA
pS6 ELISA was performed as previously described (26) with minor modifications. The
pAKT ELISA assay was performed as follows: PC-3 (ATCC) cells were seeded at
1.5×105 cells per well in 6-well plates (NUNC, 140685) in growth medium then
incubated at 37°C, 5% CO2 for 72 h, and the growth medium was replaced with serum-
free DMEM. Serial dilutions of the test compound in 0.3% DMSO (vehicle) were added
to the cells and incubated for 2 h and 50 min. Cells were then stimulated with 100 ng/ml
EGF (R&D Systems, 236-EG) for 10 min. Cells were washed once with ice-cold PBS,
harvested by briefly shaking in 100 µl of TENN lysis buffer (20 mM Tris-HCl, pH 7.5, 1
mM EDTA pH 8.0, 0.5% NP40, 150 mM NaCl) with protease and phosphatase inhibitors
(1 mM PMSF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 µg/ml pepstatin, 1 mM EDTA, 1
mM NaF, 20 mM β-glycerophosphate, 1 mM Na-orthovanadate, and 5 mM p-nitrophenyl
phosphate), and transferred to 96-well plates. Cells were lysed on ice for 20 min by
pipetting up and down 10 times, and the supernatants were collected by centrifugation.
ELISA assays for pAKTT308 and total AKT were performed with the AKT[pT308]
ELISA kit (Biosource, KHO0201) and AKT ELISA kit (Biosource, KHO0101). IC50
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 10
values were determined based on the ratio of pAKT to total AKT signal in lysates from
compound-treated cells, normalized to lysates from DMSO-treated controls.
PI3K Pathway Profiling Western Immunoblot Analysis
PC 3, MCF7, A549 ,U87-MG, LS174T, MDA-MB-468, and OVCAR 3 cells were seeded
at densities of 2×106, 2×106, 1.2 ×106, 2×106, 2×106, 1.2 ×106,and 1×106 cells,
respectively, onto 10 cm dishes in in their respective culture medium and incubated at
37°C, 5% CO2 for 20-47 h. . The medium was replaced with test compounds dissolved in
the same media containing 0.3% DMSO, and the cells were incubated for 3 h. For growth
factor treatment, the medium was replaced with test compounds dissolved in serum-free
DMEM containing 0.3% DMSO. After incubation for 3 h, cells were stimulated with
100 ng/ml of EGF (R&D Systems, 236-EG) for 10 min. Cells were washed with ice-cold
PBS, and directly lysed with cell lysis buffer (Biosource International, FNN0011)
containing protease inhibitors (Complete-Mini, EDTA-free, Roche, 11836170001;
Aminoethylbenzenesulfonyl fluoride, Sigma, A8456). Protein lysates were analyzed by
western immunoblotting. PVDF membranes (Invitrogen) were incubated overnight at
4°C with primary antibodies at the indicated concentrations in 3% BSA/TBST buffer,
followed by incubation for 1 h with a 1/10000 dilution of secondary goat anti-rabbit HRP
antibody (CST#7074) or a 1/3000 dilution of secondary goat anti-mouse HRP antibody
(Amersham, NXA931) in 5% non-fat milk/TBST. Signals were detected using ECL-plus
(Amersham, RPN2132) and scanned using a Typhoon 9400 scanner (Molecular Devices).
For total protein readouts, stripped membranes were incubated with the respective
primary antibodies, with signal detection as described above. Scans were analyzed using
ImageQuant software. Phospho signals were normalized to the corresponding total
protein signals, % inhibition relative to DMSO control was determined, and IC50 values
were calculated using XLfit4 software. The following antibodies were used in Western
Immunoblot analysis: pAKT (T308) (CST#4056, 1/500 dilution), pAKT (S473)
(Biosource, 44-622G, 1/1000), AKT (Biosource, 44-607G, 1/1000 dilution), pp70S6K
(T389) (CST #9234, 1/1000 dilution), p70S6K (Bethyl, A300-510A, 1/2500 dilution),
pS6 (S240/244) (CST #2215, 1/2000 dilution), S6 (CST #2217, 1/2000 dilution),
pPRAS40 (T246) (Biosource, 44-1100G, 1/2000 dilution), PRAS40 (Biosource
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 11
AHO1031, 1/1000 dilution), pGSK3β (S9) (CST #9336, 1/1000 dilution), GSK3β (CST
#9315, 1/1000 dilution), p4EBP1 (T37/46) (CST #9459, 1/1000 dilution), 4EBP1 (CST
#9452, 1/1000 dilution), Cyclin D1 (EMD Biosciences, CC12, 1/1000 dilution), pERK
(Y204) (Santa Cruz, sc-7383, 1/1000 dilution) and ERK (CST #9102, 1/1000 dilution).
mTOR Pathway Assay in Ramos Cells
Ramos (ATCC) cells were seeded at a density of 0.3×106 cells/mL in growth medium. .
The next day, cells were centrifuged, washed with serum-free medium supplemented
with 1% bovine serum albumin (BSA, tissue culture tested, Sigma, A4919), resuspended
in RPMI supplemented with 1% BSA, and incubated for 20 h. The serum-starved cells
were centrifuged and resuspended in 5 mL of the saved media at 1×106 cells/mL. Cells
were treated with test compound administered at a final DMSO concentration of 0.3%.
For the nutrient-depletion control, the serum-starved cells were washed once with PBS,
and resuspended in 5 mL of PBS with 0.3% DMSO. After incubation for 2 h, cells were
washed once in PBS and lysed in 150 µL of Biosource cell lysis buffer containing
protease inhibitors (Complete-Mini, EDTA-free, Roche; AEBSF, Sigma). Lysates were
analyzed by western immunoblotting. PVDF membranes were incubated overnight at 4°C
with 1/500 dilution of rabbit anti-pmTOR (CST#2974), with 1/1000 dilution of rabbit
anti-pp70S6K (CST#9234), or with 1/1000 dilution of rabbit anti-p4E-BP1 (CST#9459)
in 3% BSA/TBST, followed by incubation for 1 h with a 1/10000 dilution of secondary
goat anti-rabbit HRP antibody (CST#7074) in 5% non-fat milk/TBST and signals
detected and analyzed as described above. For detection of total p70S6K and total
4E-BP1, stripped membranes were probed with rabbit anti-total p70S6K (1/2500, Bethyl,
A300-510A) and with rabbit anti-total p4E-BP1 (1/1000, CST#9452) with signals
detected and analyzed as described above.
Cell Proliferation and Cytotoxicity Assays
Cellular proliferation was assessed as previously described (27) using the Cell
Proliferation ELISA, Bromo Deoxyuridine (BrdU) chemiluminescence kit (Roche,
Applied Science). Cytotoxicity was assessed using the ATP Bioluminescence Assay as
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 12
follows: PC-3, MCF7, A549 , LS174T, MDA-MB-468, U87-MG, and OVCAR-3 cells
were plated at densities of 7×103, 1.5×104, 6×103, 7×103,7×103, 6×103, 1.5×104 cells/well,
respectively, onto 96-well microtiter plates (Corning, 3904) in culture medium, incubated
at 37°C, 5% CO2 for 18 h, and then treated with a serial dilution of compound in medium
containing a final concentration of 0.3% DMSO. Triplicate wells were used for each
compound concentration. Control wells received 0.3% DMSO in media. Cultures were
incubated at 37°C, 5% CO2 for an additional 24 h and cells were then assayed for
viability using the ViaLight™ HS kit (Cambrex, LT07-111).
Apoptosis Assay (Caspases 3/7 Assay)
PC 3, MCF7, A549, LS174T, MDA MB 468, U87 MG and OVCAR-3 cells were plated
at densities of 5×103, 1.2×104, 5×103, 6×103, 6×103, 5×103 and 1.2×104 cells/well ,
respectively, onto 96-well microtiter plates (Corning, 3904), in culture medium at 37°C,
5% CO2 for 18 h, and then treated with a serial dilution of compound in medium
containing a final concentration of 0.3% DMSO. Triplicate wells were used for each
compound concentration. Positive control wells received 5-30000 nM adriamycin (MCF7,
A549, and LS174T) or 5-30000 nM camptothecin (PC-3, U87-MG, OVCAR-3, and
MDA-MB-468) and negative control wells received 0.3% DMSO in media. Background
wells contained no cells and 0.3% DMSO in media. Following incubation at 37°C, 5%
CO2 for an additional 48 h, apoptosis was assessed using the Apo-ONETM Homogeneous
Caspase-3/7 Assay kit (Promega, G7791). EC50 values were calculated based on the
fluorescence of compound-treated wells compared to that of the corresponding positive
control.
Anchorage-Independent Growth Assay (Soft Agar Assay)
Soft agar (60 µl/well of 0.75%, BD Biosciences) was plated in a 96-well black plate
(Nalge Nunc International) and allowed to solidify at 37°C for 20 min. 4.8×103 PC-3 or
MCF7 cells in 100 µl of media containing 0.375% agar, FBS (15% for PC-3 and 20% for
MCF7), and 1x concentrations of serial dilutions of XL765 were layered over the base
agar. After 10 min, 60 µl of DMEM (GIBCO) containing FBS and 2-fold concentrated
test compounds were added over the cell layer. Following equilibration of the media and
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 13
the test compound, the final compound concentration was presumed to be 1× in all three
layers. The cultures were incubated for 14 days at 37°C, 5% CO2. At day 7, 50 µl of fresh
media containing 10% FBS without compound was added to keep the cultures from
drying out. At the completion of the incubation, the media in the top layer was removed,
and 40 µl of media containing 50% Alamar BlueTM (Biosource, DAL1025) were added to
each well followed by incubation at 37°C, 5% CO2 for 4 h and subsequent fluorescent
detection.
Migration Assay
The HGF-induced chemotaxis assay was performed as previously described (27).
PC-3, MCF7 and B16F10, Cytotoxicity Assays (Alamar Blue Assay)
PC-3 (ATCC), MCF7 (ATCC) and B16F10 (ATCC) cells were mixed with a series of
diluted compounds in serum-free DMEM (Gibco), DMEM containing 0.2% FBS, and
serum-free EBM-2 medium (Clonetics), respectively. Control wells received media with
0.25% DMSO alone. 5×103 cells were plated in each well of a 96-well plate and
incubated at 37°C, 5% CO2 for 18 h (PC-3) or 24 h (B16F10 and HMVEC-L). At the end
of the incubation, cell viability was determined using Alamar Blue solution (Biosource).
Studies in tumor-bearing mice
Tumors were collected at the indicated time-points and tumor lysates were prepared as
previously described (25). Pooled lysates were analyzed by western immunoblotting.
PVDF membranes were incubated overnight at 4°C with primary antibodies to the
respective phosphoepitopes at the indicated concentrations in 3% BSA/TBST buffer. The
membranes were then incubated for 1 h with a 1/10000 dilution of secondary goat
anti-rabbit HRP antibody (CST#7074) in 5% non-fat milk/TBST. Signals were detected
using ECL-plus (Amersham, RPN2132) and scanned using Typhoon (Molecular
Devices). To determine total protein levels, membranes were stripped and incubated with
the indicated primary antibodies specific for the respective total proteins. The same
procedure described above was followed to detect the total protein signal. Scans were
analyzed using Image Quant software. % inhibition was determined by normalizing the
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 14
phosphoepitope signals to the total protein signals and then calculating % inhibition
compared to vehicle control groups. The following antibodies were used in western
immunoblot analysis of tumor extracts : pAKT (T308) (CST#4056, 1/500 dilution),
pAKT (S473) (CST #9271, 1/1000), AKT (CST #9272, 1/1500 dilution), pp70S6K
(T389) (CST #9234, 1/500 dilution), p70S6K (Bethyl, A300-510A, 1/2000 dilution), pS6
(S240/244) (CST #2215, 1/2000 dilution), and S6 (CST #2217, 1/1500 dilution).
In vivo efficacy studies were performed in athymic nude mice purchased from Taconic
(Hudson, NY) and housed according to the Exelixis Institutional Animal Care and Use
Committee guidelines. Tumor cells were cultured in vitro in DMEM (Mediatech,
Manassas, VA) supplemented with 10% fetal bovine serum (20% for PC-3 and OVCAR-
3 cells), penicillin-streptomycin and nonessential amino acids at 37°C in a humidified 5%
CO2 atmosphere. On day 0, cells were harvested by brief trypsinization, and 1 to 5×106
cells in 0.1 mL ice-cold Hanks Balanced Salt Solution (HBSS) were implanted
subcutaneously (OVCAR-3) or intradermally (MCF7, U-87 MG) into the hind flank of
female athymic nude mice. In the case of the MCF7 model an estrogen pellet (IRA,
Sarasota, FL) was implanted subcutaneously at the nape of neck at the time of tumor cell
implantation. 3x106 PC-3 cells were similarly harvested and implanted subcutaneously
into the hind-flank of 5-8 week old male nude mice. Tumor growth was monitored
weekly with calipers until staging and dose initiation. During the dosing period, body and
tumor weights were assessed as previously described (27). XL765 was formulated in
sterile water/10 mM HCl or water and administered at the indicated doses and regimens
by oral gavage at a dose volume of 10 mL/kg.
Histology
After euthanasia, tumors from animals administered XL765 and/or other agents were
excised and fixed in zinc fixative (BD Pharmingen) for 24-48 h before being processed
into paraffin blocks. Five µm thin sections were cut serially to represent the largest
possible surface for each tumor and stained using standard immunohistochemical
methods to detect Ki67 nuclear antigen (Lab Vision) and CD31 positive tumor vessels
(BD Pharmingen). CD31 was detected by biotinylated secondary antibody followed by
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 15
avidin-biotin-peroxidase complex (BD Pharmingen). Ki67 was detected by Envision+
anti-rabbit peroxidase complexed polymer (DAKO). Sections were counterstained with
hematoxylin. Tumor mean vessel density and Ki67 index in tumor sections were
quantified using the ACIS™ automatic cellular imaging system (Clarient Inc., San Juan
Capistrano, CA). The mean number of tumor vessels per mm2 was determined by
analyzing eight to 15 fields across the total tumor section. Percent Ki67 positive tumor
cells was determined by sampling multiple representative fields of equal size across the
total viable tumor area of each section and dividing the number of Ki67 positive cells by
the total number of cells identified per field. Apoptosis was assessed by TUNEL as
previously described (27).The results for each IHC readout was averaged for each tumor
section, followed by averaging the results for each treatment group (n = 9-10). Statistical
analyses were performed using the standard two-tailed t-test with Bonferroni adjustment
for multiple comparisons against a single control group.
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 16
Results
XL765 is a selective inhibitor of Class I PI3Ks and of mTOR in biochemical assays
XL765 (Figure 1A) was identified following optimization of a pyridopyrimidinone
scaffold for in vivo PI3K/mTOR pathway inhibition and drug-like properties. In assays
performed using purified proteins in a luciferase-coupled chemiluminescence format,
XL765 displayed potent inhibitory activity against Class I PI3K isoforms p110α, p110β,
p110δ, and p120γ, with IC50 values of 39, 110, 43, and 9 nM, respectively (Table 1). The
IC50 value for inhibition of PI3Kα by XL765 was determined at various concentrations of
ATP, revealing XL765 to be an ATP-competitive inhibitor with an equilibrium inhibition
constant (KI) value of 13 nM.
XL765 also inhibited mTOR (IC50 values of 160 and 910 nM for mTORC1 and
mTORC2, respectively) in an immune-complex kinase assay and the PI3K-related kinase
DNA PK (IC50 value of 150 nM). In contrast, XL765 had relatively weak inhibitory
activity towards the Class III PI3K vacuolar sorting protein 34 (VPS34; IC50 value of ~
9.1 µM). XL765 was also profiled against a panel of ~130 protein kinases; no cross-
reactivity was observed at concentrations below 1.5 µM (Supplemental Table S1). All
assays were performed at ATP concentrations approximately equal to the Michaelis
constant (KM) values of the respective enzymes.
XL765 inhibits the PI3K pathway in multiple tumor cell models
MCF7 human mammary carcinoma cells and PC-3 human prostate adenocarcinoma cells
were selected for the initial assessment of the effect of XL765 on signaling downstream
of PTEN/PI3K since they each have a prevalent genetic lesion that activates the PI3K
pathway. MCF7 cells carry a heterozygous E545K activating mutation in the p110α
subunit of PI3K and PC-3 cells carry a homozygous deletion of exons 3-9 of the PTEN
tumor suppressor gene. PIP3 is the product of a class I PI3Ks acting on the physiological
substrate PIP2. Hence PIP3 levels serve as a direct assessment of PI3K activity.
Consistent with its inhibitory activity against purified PI3K proteins, XL765 inhibited
EGF induced PIP3 production in PC-3 and MCF7 cells with IC50 values of 290 and 170
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 17
nM, respectively (Table 2). The ability of XL765 to inhibit phosphorylation of key
signaling proteins downstream of PI3K was examined by assessing its effects on EGF
stimulated phosphorylation of AKT and on non-stimulated phosphorylation of S6 in PC-3
cells by cell based ELISA. XL765 inhibited these activities with IC50 values of 250 and
120 nM, respectively (Table 2).
The effects of XL765 on the PI3K signaling pathway were then examined by Western
immunoblot analysis in PC-3 and MCF7 cells (see Figure 1B and Supplemental Figure
S1). The results were consistent in both cell lines. XL765 inhibits AKT phosphorylation
at both activation sites (T308 and S473) at concentrations consistent with the IC50 values
determined by ELISA. The T308 phosphorylation site on AKT is a substrate for PDK1
(1), whereas the S473 site is a substrate for mTORC2 (6). Inhibition of AKT substrate
phosphorylation (PRAS40 and GSK3β) and inhibition of phosphorylation events
downstream of mTOR (p70S6K, S6, and 4EBP1 phosphorylation) were also evident.
XL765 induces a decrease in the levels of cyclin D1 protein, consistent with increased
GSK3β activity as a result of inhibition of AKT leading to GSK3β-mediated
phosphorylation and subsequent degradation of Cyclin D1 (Figure 1B). Overall, a similar
range of compound concentrations was required to inhibit PI3K proximal
phosphorylation events (AKT T308 phosphorylation) and phosphorylation events
downstream of mTORC1 and mTORC2 (p70S6K phosphorylation and AKT S473
phosphorylation).
The control compound ZSTK474 (an inhibitor of PI3K; Reference 28) at 10 µM robustly
decreased the levels of all the phospho readouts assessed. The TORC1 inhibitor
rapamycin at 0.1 µM did not inhibit the phosphorylation of AKT or its direct substrates
PRAS40 and GSK3β, but in fact appeared to stimulate phosphorylation of AKT. This is
consistent with relief of p70S6K-dependent negative feedback of PI3K (see
Introduction). As expected, rapamycin significantly decreased p-p70S6K and pS6 levels,
consistent with its well characterized ability to inhibit mTORC1. None of the compounds
had significant effects on ERK1/2 phosphorylation, consistent with biochemical profiling
data. XL765 was further profiled in additional cell lines bearing a variety of genetic
lesions that activate/modulate the PI3K pathway. These were OVCAR-3 (PIK3CA
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 18
amplification), U87-MG (PTEN deletion), A549 (KRAS mutation, loss-of-function
mutation in the mTOR-directed tumor suppressor gene LKB-1), MDA-MB-468 (PTEN
deletion) and LS174T (PIK3CA and KRAS mutations) cells. XL765 demonstrated
consistent activity in these cell lines with no marked differences in sensitivity being
evident (Supplemental Figures 2 and 3).
XL765 inhibits PI3K-independent mTOR signaling
In order to directly assess the impact of XL765 on mTOR in cells, we employed an
approach that relies on the ability of nutritional signals to activate mTOR independent of
PI3K activity. Regulation of mTOR signaling by nutrient availability is predominant in
certain transformed B cells (29), and we used the Burkitt lymphoma derived cell line
Ramos as a system to study the effect of XL765 on nutrient dependent mTOR activity
(Figure 1C). Cells were starved in serum free media for 20 h, and then treated with
compounds, DMSO, or serum free and nutrient free PBS for 2 h. Cell lysates were
prepared and analyzed by gel electrophoresis and Western immunoblotting with anti-
pmTOR, anti-p-p70S6K, and anti-p4EBP1 antibodies. Cells incubated in PBS show very
low levels of phosphorylation of p70S6K, 4EBP1 or the mTOR autophosphorylation site
S2481, consistent with low mTOR activity. Incubation of cells in serum free, nutrient
containing media results in a robust upregulation of mTOR-dependent phosphorylation
events. ZSTK474 and PI-103 (30) at 10 µM inhibit these phosphorylation events,
consistent with their ability to directly inhibit mTOR kinase activity in addition to PI3K
activity. Rapamycin treatment at 1 µM resulted in little if any decrease in mTOR
autophosphorylation, but profoundly inhibited p70S6K phosphorylation consistent with
selective inhibition of mTORC1. XL765 inhibited nutrient-dependent phosphorylation at
all sites, with IC50 values of 160, 340, and 3000 nM, for mTOR S2481, p70S6K, and
4EBP1 phosphorylation respectively. These results are consistent with the mTOR kinase
assay results presented above, and provide further evidence that XL765 is a direct
inhibitor of mTOR kinase activity.
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 19
Effects on Proliferation in a Panel of Tumor Cell Lines
In MCF7 and PC-3 cells, XL765 inhibits proliferation (monitored by BrdU incorporation)
with IC50 values of 1070 nM and 1840 nM respectively. When tested in a broad panel of
tumor cell lines with diverse origins and genetic backgrounds, XL765 was found to
inhibit proliferation with a wide range of IC50 values (200 nM to >30000 nM; Figure 2
and Supplemental Table S2). A breakdown of sensitivity by genotype suggested that
PIK3CA mutant cell lines tended to be relatively sensitive to XL765, whereas RAS or
BRAF mutant cell lines tended to be less sensitive. Interestingly, several RAS mutant cell
lines were relatively insensitive to XL765 in spite of their also harboring PIK3CA
mutations (Figure 2 and Supplemental Table S2). Cell lines with loss of PTEN showed a
range of sensitivities, with some (e.g. the prostate carcinoma lines ZR75-1, LNCap and
PC-3) being sensitive and others (e.g the glioblastoma cell lines U251, U373) being
refractory.
Anchorage-independent growth in soft agar is considered the most stringent assay for
detecting malignant transformation of cells. To further characterize the effects of XL765
on tumor cell growth, an assay monitoring the anchorage-independent growth of PC-3
and MCF7 cells in soft agar over a 14-day period was employed. XL765 inhibits colony
growth with an IC50 of 270 nM in PC-3 cells and 230 nM in MCF7 cells. These IC50
values are significantly lower than those required to inhibit growth of the cells in a
monolayer, perhaps indicating an increased reliance on PI3K pathway signaling for
growth in 3-dimensions.
To rule out direct cytotoxic effects of XL765 on tumor cells, its effects on cell viability
were determined by bioluminescent measurement of cellular ATP. XL765 did not reduce
ATP levels in cells when incubated for 24 h, indicating a lack of acute cytotoxicity
(Supplemental Table S2, footnote). Induction of cytoplasmic Caspases 3 and 7 was
examined as an indication of apoptosis induction. XL765 did not affect the activity of
these Caspases at the doses and time point tested (Supplemental Table S2, footnote). In
MCF7 cells, the anti-proliferative effects of XL765 were associated with a specific block
in the G1 phase of the cell cycle and an increase of sub G1 cell population (data not
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 20
shown). Therefore, at least in MCF7 cells, XL765 exhibits anti-proliferative effects
predominantly via blockade of the cell cycle rather than through cytotoxic or apoptotic
effects.
XL765 inhibits tumor cell migration
One of the hallmarks of aggressive tumor cells is the ability to migrate in response to
chemotactic stimuli and to invade surrounding tissue. HGF is one of the key stimulators
of these behaviors, and cell lines expressing high levels of the HGF receptor MET, are
highly invasive and metastatic in vivo. Since PI3K resides in the MET signaling pathway,
the ability of XL765 to inhibit HGF-stimulated migration was tested in vitro. Murine B16
melanoma cells express high levels of Met which becomes highly phosphorylated when
the cells are treated with HGF. In 10% serum, B16 cells plated in the top well of a
transwell chamber containing a barrier with 0.8 micron pores show very little ability to
migrate to the lower chamber side. Addition of HGF to the lower transwell chamber
greatly increases migration through the barrier over a 24 h period. XL765 blocks this
effect with an IC50 value of 601 nM (Supplemental Figure S4). The cytotoxicity IC50
value of XL765 in B16 cells is 7300 nM, 12-fold higher than the IC50 value for inhibition
of migration. Therefore, inhibition of melanoma cell migration by XL765 is unlikely to
be due to cytotoxicity.
XL765 inhibits the PI3K and mTOR pathways and displays robust anti-tumor
activity in tumor bearing mice
Lysates derived from MCF7 xenograft tumors intradermally implanted into athymic nude
mice contain high levels of constitutively phosphorylated AKT, p70S6K, and S6 proteins.
The ability of XL765 to inhibit endogenous phosphorylation of AKT, p70S6K, and S6
was examined following a single oral dose of 10, 30, 100, or 300 mg/kg. The tumors
were harvested 4 h, 24 h, or 48 h post-dose and homogenized in lysis buffer. Tumor
lysates from each animal (n=4) were then pooled for each group and analyzed for levels
of total and phosphorylated AKT, p70S6K, and S6 by western immunoblotting
(Figure 3A).
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 21
Oral administration of XL765 causes a dose-dependent decrease of phosphorylation of
AKT, p70S6K, and S6 in the tumors, reaching a maximum of 84% inhibition of S6
phosphorylation at 30 mg/kg at 4 h. The dose response relationships (not shown) derived
from the 4 h time point predict 50% inhibition of AKT, p70S6K, and S6 phosphorylation
to occur at doses of 19 mg/kg (pAKTT308 and pAKTS473), 51 mg/kg (p-p70S6K), and
18 mg/kg (pS6). Inhibition of AKT, p70S6K, and S6 phosphorylation in MCF7 tumors
following a 30 mg/kg dose of XL765 was maximal at 4 h, reaching 61-84%; however, the
level of inhibition decreased to 0-42% by 24 h, and minimal or no inhibition was evident
by 48 h (see Figure 3A). Following a 100 mg/kg dose of XL765, inhibition was also
maximal at 4 h (52-75%). However, in contrast to the 30 mg/kg dose, inhibition at 24 h
(48-71%) was almost comparable to that seen at 4 h. Partial inhibition of some
phosphoepitopes persisted through 48 h (Figure 3A).
Similarly, administration of XL765 caused a dose-dependent decrease of phosphorylation
of AKT, p70S6K, and S6 in PC-3 tumors in vivo, reaching a maximum of 93% inhibition
of AKT phosphorylation at 300 mg/kg at 4 h post-dose (Figure 3B). The dose response
relationships (not shown) derived from the 4 h time point predict 50% inhibition of AKT,
p70S6K, and S6 phosphorylation to occur at doses of 15 mg/kg (pAKTT308), 13 mg/kg
(pAKTS473), 59 mg/kg (p-p70S6K), and 48 mg/kg (pS6). Consistent with the MCF7 data,
for the 100 mg/kg dose inhibition (42-60%) persisted through 24 h post dose. In both
studies, blood was collected at the same time tumor tissue was harvested and plasma
concentrations of XL765 were assessed (Supplemental Table S3). Based on these data,
the plasma concentrations associated with inhibition of phosphorylation of AKT,
p70S6K, and S6 by 50% in these tumor models ranged from approximately 3 to 9 µM.
Hence, XL765 exhibited comparable pharmacodynamic activity in PIK3CA-mutant
MCF7 and PTEN-deficient PC-3 xenograft tumor models.
Multiple tumor models were utilized to explore the efficacy and potency of repeat-dose
oral administration of XL765 with regards to tumor growth inhibition in vivo. In addition
to the previously described MCF7 and PC-3 models, the anti-tumor efficacy of XL765
was evaluated in xenograft models including OVCAR-3 (human ovarian xenograft tumor
model exhibiting PIK3CA amplification), U-87 MG (human glioblastoma xenograft
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 22
tumor model harboring a deletion at codon 54 in the gene encoding PTEN, resulting in a
frameshift), A549 (human NSCLC xenograft tumor model harboring a homozygous
activating mutation in KRAS2 and a homozygous loss-of-function mutation in LKB1) and
Calu-6 (human NSCLC xenograft tumor model harboring an activating mutation in
KRAS2).
XL765 administration results in significant anti-tumor efficacy in vivo in all of these
models (Figure 4) at doses that proved well tolerated as assessed by daily monitoring of
mouse weights (Supplemental Figure S5; no or minimal impact on body weights
compared with vehicle control). The most efficacious schedules were 30 mg/kg bid and
100 mg/kg q2d, which suggests that sustained pathway inhibition is required for maximal
effect on tumor growth. These schedules generally resulted in stasis of tumor growth,
except in the PC-3 model and the Calu-6 KRAS mutant NSCLC model, where tumors
continued to grow although at a reduced rate. Immunohistochemical analyses of MCF7,
PC-3 and A549 tumors collected at the end of the dosing period revealed significant,
dose-dependent decreases in staining for Ki67, a marker of cell proliferation. Moreover,
XL765 administration was associated with increased tumor cell apoptosis in MCF7 and
A549 tumors and modestly decreased tumor vascularization in MCF7, PC-3 and A549
tumors (Table 3). Thus, inhibition of PI3K and mTOR by XL765 results in anti-
proliferative, pro-apoptotic and anti-vascular effects in xenograft tumors. Plasma
concentrations at the end of these efficacy studies were similar to those seen following
single-dose administration. For example, in the MCF7 efficacy study, average plasma
concentrations for the 30 mg/kg dose administered once daily were 8.8 μM, 5.3 μM, and
below the limit of detection at the 1 hour, 4 hour and 24 h time-points, respectively (n=3
per time-point).
The anti-tumor activity observed in the sub-cutaneous U-87 MG glioblastoma xenograft
model prompted us to examine the pharmacodynamic activity of XL765 in the mouse
brain as a measure of whether the compound could effectively cross the blood-brain
barrier. Lysates from brains of non-tumor bearing mice show significant PI3K pathway
activity as judged by levels of pAKT and pS6. Four hours following a single oral dose of
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 23
30 or 100 mg/kg XL765, pAKT and pS6 levels are substantially reduced, demonstrating
that XL765 can cross the blood-brain barrier and inhibit the PI3K pathway (Figure 4).
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 24
Discussion
Previous experience with highly selective inhibitors of signal transduction pathways has
revealed the existence of unanticipated regulatory mechanisms that can act to limit the
efficacy of pathway inhibition. An example is the upregulation of AKT phosphorylation
that occurs as the result of relief of a negative feedback loop following inhibition of
mTORC1 by the rapamycin class of mTOR inhibitors. Similarly, selective B-RAF
inhibitors can trigger a “paradoxical” activation of C-RAF in the context of activated
RAS as a result of allosteric effects on B-RAF/C-RAF dimers. Inhibition at a single node
in a pathway also allows for the development of resistance via pathway activation
downstream of the point of intervention. Combining multiple inhibitors that impact the
same pathway, or developing a single compound that inhibits multiple members of a
pathway is therefore an attractive approach to limit or circumvent these issues. For
example, emerging data suggest that combinations of B-RAF and MEK inhibitors are
superior to either agent alone for the treatment of B-RAF mutant metastatic melanoma.
The PI3K/mTOR pathway is one of the most frequently activated signaling pathways in
human cancer, in part due to the mutation, amplification or deletion of key pathway
regulatory components. Activation of the pathway promotes tumor cell proliferation,
survival and resistance to anti-cancer therapies. As a result, extensive efforts are being
devoted to identifying and developing small molecule inhibitors that impact different
nodes of the pathway. Activation of the pathway is subject to regulation at multiple
points and by a wide variety of signals, including growth factors, cellular energy levels,
nutritional status and oxygenation. We therefore elected to optimize a compound that
would inhibit two key nodes in the pathway, PI3K and mTOR, with the aim of
maximizing pathway blockade in the context of multiple genetic backgrounds and under
a variety of environmental conditions.
XL765 (SAR245709) inhibits both class I PI3Ks as well as mTOR. Although XL765
appears to be more potent against PI3Kα than against PI3Kβ when assessed by
biochemical assays using purified kinases, in cellular assays XL765 shows comparable
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 25
activity versus PI3K pathway signaling in MCF7 breast (PIK3CA mutant) and PC-3
prostate (PTEN-deleted) tumor cells. PI3Kβ is considered to be the major driver of
dysregulated PI3K pathway activity associated with PTEN deficiency (31).
Moreover, XL765 showed comparably robust and persistent pharmacodynamic activity
against these cell lines when they were grown as xenograft tumors in mice. These data
demonstrate that XL765 exhibits functionally comparable activity against PI3Kα and
PI3Kβ in cultured cells and xenograft tumors.
In biochemical assays XL765 was generally less potent against mTOR than against
Class I PI3K isoforms. In tumor cells however, XL765 inhibits mTOR-dependent
phosphorylation events and PI3K-independent, nutrient-stimulated mTOR activity with a
potency comparable to that demonstrated for PI3K-dependent signaling, suggesting
potential for concerted PI3K/mTOR inhibition in cellular and in vivo models.
Our survey of the effects on XL765 on multiple phospho-epitopes in the PI3K signaling
pathway in 6 tumor cell lines with differing genetic backgrounds revealed consistent
inhibition downstream of both PI3K and mTOR. We saw no evidence for feedback
upregulation within the pathway or with respect to ERK phosphorylation. However, it is
important to note that our data are not exhaustive with respect to either genotype or
phosphorylation sites surveyed, and are limited to a single time point. The profile of
XL765 is clearly differentiated from that of rapamycin, which in all cell lines tested is a
potent inhibitor of mTORC1-dependent p70S6K and S6 phosphorylation, but in some
cell lines augmented PI3K activity as assessed by AKT phosphorylation, consistent with
previous reports.
XL765 exhibits a wide range of anti-proliferative activity against tumor cells grown as
monolayers. In MCF7 cells, these effects were associated with a G1 arrest but not with
acute cytotoxicity or induction of apoptosis. When sensitivity to XL765 is examined in
relation to genotype, there is a trend suggesting enhanced sensitivity of cells exhibiting
PIK3CA activating mutations, consistent with similar observations previously reported
for the PI3K inhibitors GDC-0941 and CH5132799 (32, 33). Likewise, the relative
insensitivity of RAS mutant cell lines, regardless of PIK3CA status, to inhibition of
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 26
proliferation by XL765 is consistent with preclinical observations with other PI3K
pathway targeting agents (23). However, we note that a number of K-RAS mutant lines
such as the A549 NSCLC line were quite sensitive to XL765. These cells have a
concomitant deletion of the LKB1 gene which may serve to sensitize them to inhibition of
mTOR. Likewise, PTEN-deleted cell lines had a wide range of sensitivities to XL765
with some being very sensitive and some being refractory. The basis for these
differences is not understood, but presumably reflects varying degrees of dependence on
PI3K pathway signaling for proliferation as a result of alterations in other pathways that
impact growth.
In multiple xenograft tumor models, oral administration of XL765 resulted in substantial
tumor growth inhibition at well tolerated doses. The most efficacious schedules were 30
mg/kg bid or 100 mg/kg q2d, suggesting that efficacy is associated with more continuous
inhibition of the pathway. These models encompass multiple genetic lesions activating
the PI3K pathway, specifically a PIK3CA E545K mutation (MCF7), PIK3CA
amplification (OVCAR-3), PTEN deletion (PC-3 and U-87 MG), KRAS mutation (A549
and Calu-6) and LKB1 mutation (A549). The fact that efficacy was observed in all these
models suggests that XL765 may have broad utility in tumors with activation of the PI3K
pathway. Based on the IHC/IF analyses conducted on tumor xenografts following repeat
dosing of XL765, anti-tumor efficacy was associated with a combination of anti-
proliferative and pro-apoptotic effects, with a modest impact on tumor angiogenesis.
These pro-apoptotic effects in vivo, which are not evident on cultured tumor cells, likely
reflect targeting of the tumor microenviroment in addition to tumor cells themselves,
which is consistent with the antiangiogenic effects evident.
In the majority of the xenograft models, complete or near complete inhibition of tumor
growth (but not regression) was observed, with the exception of the PC-3 and Calu-6
models which were relatively resistant. Overall, our data are not extensive enough to
determine whether in vitro sensitivity is generally predictive of efficacy in xenograft
models. It is also not yet clear whether the presence of PIK3CA mutations or PTEN
deficiency will be predictive of greater clinical responsiveness to PI3K pathway
inhibitors in general, although an analysis based on combining the results of multiple
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 27
early stage trials suggested that PIK3CA H1047R mutations are associated with response
(34). Intensive molecular profiling of tumors in the ongoing XL765 clinical studies is
being performed to further explore this question.
Since we observed significant anti-tumor efficacy in the U-87 MG glioblastoma model,
we assessed the pharmacodynamic activity of XL765 in mouse brain. At the same doses
associated with efficacy in the subcutaneous xenograft model, XL765 effectively
inhibited PI3K pathway signaling in the brain, supporting its potential utility for the
treatment of CNS malignancies. Consistent with this observation, XL765 has
demonstrated significant efficacy in an orthotopic glioblastoma xenograft model, both as
a single agent and in combination with temozolomide (35). In addition, recent data from
a clinical trial in which XL765 was administered to glioblastoma patients prior to surgical
removal of recurring lesions showed significant inhibition of PI3K pathway signaling in
glioblastoma tumor tissue following XL765 dosing (36). XL765 is currently in Phase I
and II clinical studies as a single agent or in combination with other targeted or cytotoxic
agents in patients with solid tumors, lymphoma, and leukemia (NCT01390818,
NCT01410513, NCT01403636).
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 28
Acknowledgements
We are grateful to Coumaran Egile for critical reading of the manuscript. Requests
relating to provision of XL765 (SAR245409) should be direct to Coumaran Egile at
sanofi (Coumaran.Egile@sanofi.com).
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 29
References
1. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase
pathway in cancer. Nat Rev Drug Discov. 2009;8:627-44.
2. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene.
2008;27:5486-96.
3. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A,
et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of
G protein-coupled receptors and is functionally redundant with p110gamma. Proc
Natl Acad Sci U S A. 2008;105:8292-7.
4. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, et al.
Role of phosphoinositide 3-OH kinase in cell transformation and control of the
actin cytoskeleton by Ras. Cell. 1997;89:457-67.
5. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol.
2010;7:209-19.
6. Guertin DA and Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell.
2007;12:9-22.
7. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H,
et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive
and raptor-independent pathway that regulates the cytoskeleton. Curr Biol.
2004;14:1296-302.
8. Febuary 2014 search of COSMIC database,
http://www.sanger.ac.uk/genetics/CGP/cosmic/
9. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of
common cancers, rare syndromes and mouse models. Nat Rev Cancer.
2011;11:289-301.
10. van Veelen W, Korsse SE, van de Laar L, Peppelenbosch MP. The long and
winding road to rational treatment of cancer associated with
LKB1/AMPK/TSC/mTORC1 signaling. Oncogene. 2011;30:2289-303.
11. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv
Cancer Res. 2009;102:19-65.
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 30
12. Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, et al. Class 1A PI3K
regulates vessel integrity during development and tumorigenesis. Proc Natl Acad
Sci U S A. 2008;105:9739-44.
13. Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, et al.
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin
inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical
imaging. Cancer Res. 2008;68:6598-607.
14. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clin Cancer Res.
2010;16:4325-30.
15. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes
J, Timorek A, et al. PIK3CA amplification associates with resistance to
chemotherapy in ovarian cancer patients. Cancer Biol Ther. 2009;8:21-6.
16. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, et al.
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to
trastuzumab but not lapatinib. Mol Cancer Ther. 2010;9:1489-502.
17. Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, et al. Differential
induction of apoptosis in HER2 and EGFR addicted cancers following PI3K
inhibition. Proc Natl Acad Sci U S A. 2009;106:19503-8.
18. Qi J, McTigue MA, Rogers A, Lifshits E, Christensen JG, Jänne PA, Engelman
JA. Multiple mutations and bypass mechanisms can contribute to development of
acquired resistance to MET inhibitors. Cancer Res. 2011;71:1081-91.
19. Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL. Breast Cancer
Special Feature: Feedback upregulation of HER3 (ErbB3) expression and activity
attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A. 2012;
109:2718-23.
20. Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr
Opin Cell Biol. 2009;21:185-93.
21. Priulla M, Calastretti A, Bruno P, Azzariti A, Paradiso A, Canti G, et al.
Preferential chemosensitization of PTEN-mutated prostate cells by silencing the
Akt kinase. Prostate. 2007;67:782-9.
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 31
22. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, et
al. Dual targeting of phosphoinositide 3-kinase and mammalian target of
rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian
carcinoma. Clin Cancer Res. 2011;17:2373-84.
23. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and
limitations. Nat Rev Cancer. 2009;9:550-62.
24. García-Echeverría C. Allosteric and ATP-competitive kinase inhibitors of mTOR
for cancer treatment. Bioorg Med Chem Lett. 2010;20:4308-12.
25. Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, et al.
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor
receptor by EXEL-7647. Clin Cancer Res. 2007;13:3713-23.
26. Bussenius J, Anand NK, Blazey CM, Bowles OJ, Bannen LC, Chan DS, et al.
Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
Bioorg Med Chem Lett. 2012;22:2283-6.
27. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib
(XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses
metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298-308.
28. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, et al.
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J
Natl Cancer Inst. 2006;98:545-56.
29. Wlodarski, P., Kasprzycka, M., Liu, X., Marzec, M., Robertson, E. S., Slupianek,
A., et al. Activation of mammalian target of rapamycin in transformed B
lymphocytes is nutrient dependent but independent of Akt, mitogen-activated
protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I,
and serum. Cancer Res 2005; 65: 7800-7808.
30. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, et al. A dual
PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell
2006; 9: 341-349.
31. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in
cancer? Curr Opin Cell Biol. 2009;21:199-208.
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 32
32. O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, et
al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase
inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res.
2010;16:3670-83.
33. Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, Tachibana Y, et al. The
selective class I PI3K inhibitor CH5132799 targets human cancers harboring
oncogenic PIK3CA mutations. Clin Cancer Res. 2011;17:3272-81.
34. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al.
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR
signaling pathway inhibitors in early-phase clinical trials. Cancer Res.
2013;73:276-84.
35. Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, et al. Inhibition
of PI3K/mTOR pathways in glioblastoma and implications for combination
therapy with temozolomide. Neuro Oncol. 2011;13:384-92.
36. Cloughesy TF, Mischel PS, Omuro AMP, Prados M, Wen PY, Wu B, et al.
Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409
(XL765) and SAR245408 (XL147) administered as single agents to patients with
recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials
consortium study. J Clin Oncol 31, 2013 (suppl; abstr 2012).
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 33
Tables
Table 1
Kinase Inhibition Profile of XL765
Family Kinase
XL765
IC50 (nM)
PI3K
Class IA
PI3Kα 39 ± 10
PI3Kβ 110 ± 30
PI3Kδ 43 ± 3
Class IB PI3Kγ 9 ± 3
Class III VPS34 9060
PI3K-related
mTORC1 160 a
mTORC2 910 a
DNA-PK 150
DNAPK, DNA protein kinase; IC50, concentration required for 50% target inhibition; mTORC1/2, mammalian target of rapamycin complex 1/2; PI3K, phosphatidylinositol 3-kinase; VPS34, vacuolar sorting protein 34.
a Immunoprecipitation kinase assay using cell lysates.
Table 2
Effects of XL765 on PIP3 Production and AKT and S6 Phosphorylation
Cell Line PIP3 IC50 (nM) pAKT IC50 (nM)a pS6 IC50 (nM)a
PC-3 290 250 120
MCF7 170 ndb ndb
See Materials and Methods for details. aIC50 values determined using ELISA assay. bnd, not determined
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 34
Table 3
Immunohistochemical Analysis of Proliferation, Vascularization and Apoptosis in
MCF7, PC-3, and A549 Xenograft Tumors
Group
Ki67 Analysis CD31 Analysis Apoptotic Index
(TUNEL)
% Positive
Cellsa
%
Reductionb MVDc
%
Reductionb
% Positive
Cells
Fold
Increaseb
MCF7
Vehicle, 10 ml/kg PO QD 43 ± 4 na 50 ± 7 nd 1.0 ± 0.5 na
XL765, 10 mg/kg PO QD 37 ± 5 15 (ns) 28 ± 4 44 3.8 ± 2.5 4 (ns)
XL765, 30 mg/kg PO QD 27 ± 6 39 33 ± 12 34 (ns) 5.3 ± 1.6 6
XL765, 30 mg/kg PO BID 23 ± 3 48 23 ± 7 54 3.5 ± 1.8 4
XL765, 100 mg/kg PO Q2D 7 ± 8 84 41d 18 36 ± 8 37
PC-3
Vehicle, 10 ml/kg PO QD 21 ± 2 na 34 ± 4 na nd nd
XL765, 30 mg/kg PO QD 13 ± 4 37 28 ± 6 17 (ns) nd nd
XL765, 30 mg/kg PO BID 10 ± 2 51 27 ± 4 19 nd nd
XL765, 100 mg/kg PO Q2D 18 ± 2 16 26 ± 3 22 nd nd
A549
Vehicle, 10 ml/kg PO QD 32 ± 5 na 37 ± 8 na 1.0 ± 0.3 na
XL765, 30 mg/kg PO QD 21 ± 3 33 35 ± 10 6 (ns) 3.8 ± 0.7 3.8
XL765, 30 mg/kg PO BID 16 ± 3 50 29 ± 6 22 3.1 ± 0.3 3.1
XL765, 100 mg/kg PO Q2D 20 ± 2 39 31 ± 8 18 (ns) 7.1 ± 0.7 7.1
XL765, 100 mg/kg PO BIW 22 ± 4 33 34 ± 6 8 (ns) 6.1 ± 1.7 6.1 aValues are mean ± standard deviation. bValues are relative to vehicle control (in all cases p < 0.05 except where indicated as ns, not significant). cMean Vessel Density. dBased on one evaluable tumor (insufficient viable tissue to score in 8 of 9 tumors).
na, not applicable; nd, not determined.
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 35
Figure Legends Figure 1
(A) Chemical structure of XL765 (SAR245409). (B) XL765 inhibits PI3K pathway
signaling in EGF-stimulated MCF7 cells. After incubation with XL765 at the indicated
concentrations, PI-103 (10 μM), ZSTK474 (10 μM), or rapamycin (0.1 μM), MCF7 cells
were stimulated with 100 ng/ml of EGF for 10 min. The cells were then lysed and effects
of compound on PI3K pathway signaling assessed by western immunoblotting. (C)
XL765 inhibits nutrient-dependent mTOR signaling pathway in Ramos cells. Cells were
starved in serum free media for 20 h, then treated with compounds at the indicated
concentrations, DMSO, or serum- and nutrient-free PBS for 2 h. Cell lysates were
prepared and analyzed by western immunoblotting
Figure 2
Relative sensitivity of tumor cells to XL765 as a function of genetic status. a Cell
proliferation IC50 values are presented normalized to that for BT474 (most sensitive cell
line). See Materials and Methods and Supplemental Table S2 for details.
Figure 3
Administration of XL765 inhibits PI3K pathway signaling in MCF7 and PC-3 tumors. A
single dose of XL765 or vehicle was administered by oral gavage to MCF7 (A) or PC-3
(B). Tumors were resected at the indicated times post dose and the effects of XL765 on
phosphorylation of AKT, p70S6K, and S6 were assessed by western immunoblotting.
Figure 4
XL765 administration results in tumor growth inhibition of established xenograft tumors.
(A) MCF7, (B) PC-3, (C) OVCAR-3, (D) U87-MG, (E) A549 or (F) Calu-6 tumor cells
were implanted and when tumors reached ~100 mg in size administration of vehicle or
XL765 was initiated at the indicated doses and regimens (Day 0/1 = day of grouping;
dosing was initiated on Day 1). Data points represent the mean ± standard error for each
treatment group (N = 9–10). (D) The inset panel in the U-87 MG tumor growth inhibition
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MS# MCT-13-0709 Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409) 36
graph shows the effect of XL765 at the indicated oral dose on pAKT and pS6 levels in
normal mouse brain at 4 h post dose.
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
N
N
ON
N
A
N
NN
B
a0O K
+ EGF
O 03
XL765 (nM)
Rap
a
3000
0
6000
9.6
240
481200
DM
SO
ZS
TK
DM
SO
PI-
10
pAKTT308
pAKTS473
AKT
pp70S6KT389
pS6S240/S244
S6
PRAS40
p70S6K
pPRAS40T246
4EBP1
GSK3β
Cyclin D1
pGSK3βS9
p4EBP1T37/T46
C
10µ
M
100n
M
OO
XL765 (µM)
pERKY204
ERK
Cyclin D1
pmTORS2481
pp70S6KT389
4EBP1T37/T46
p70S6K
ZS
TK
Rap
a
DM
SO
PB
S
0.3
30 10 3 1 0.1
DM
SO
Yu et al, Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409)
Figure 1. (A) Chemical structure of XL765 (SAR245409). (B) Effects of XL765 on PI3K Signaling Pathway in EGF-Stimulated MCF7 Cells. (C) XL765 inhibits Nutrient-Dependent mTOR Signaling Pathway in Ramos Cells
p4EBP1T37/T46
4EBP1
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
120
140RAS MutBRAF MutPTEN Mut
PIK3CA Mut/Amp
PIK3CA/RAS PTEN/BRAFPTEN/RAS
60
80
100
mal
ized
IC50
a
20
40
No
rm
0
BT474T47D
OVCAR-3
MCF7H508
IGROV-1
MDA-MB-453
SK-OV-3AGS
LS174T
HCT116H460
ZR75-1
LNCaPPC3
JRT3-T3.5BC-3
U87-MG
OPM-2 H4
H446U937
786-O
MDA-MB-468U251U373
MOLT4
WM-266
A2058
SK-MEL-28
SK-MEL-3
Colo-205
SK-HEP-1A375
HT29
OCI-AML3LoVo
RPMI8226
HL-60A549
AsPC-1H441
Capan-1
MDA-MB-231T
HT-1080
PANC-1
DLD-1
OVCAR-5
MiaPaCa
CALU-6
TALL-1
SW480
SHP-77
Yu et al, Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409)
Figure 2Sensitivity to proliferation inhibition by genotype
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
MCF-7
AA XL765
Dose (mg/kg) 10 30 100 10 30 100 10 30 100Time (h) 4 4 4 4 24 24 24 24 48 48 48 48
pAKTT308
AKT
XL765 XL765
p-p70S6KT389
p70S6K
pS6S240/S244
pAKTS473
AKT
PC-3
S6
p
B
pAKTT308
AKT
Dose (mg/kg) 10 30 100 300 10 30 100 300
Time (h) 4 4 4 4 4 24 24 24 24 24
XL765 XL765
p-p70S6KT389
p70S6K
pS6S240/S244
AKT
pAKTS473
AKT
S6
pS6S240/S244
Yu et al, Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409)
Figure 3Inhibition of AKT, p70S6K, and S6 Phosphorylation in MCF7 and PC-3 XenograftTumors after a Single Oral Dose
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
A B
DC
Vehicle 10 30 100 mg/kg
normal brain
pS6S240/S244
pAKTT308
pAKTS473
AKT
S6
g g
FE
Figure 4Anti-tumor efficacy of XL765Yu et al, Pharmacodynamics and anti-tumor efficacy of XL765 (SAR245409)
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709
Published OnlineFirst March 14, 2014.Mol Cancer Ther Peiwen Yu, A. Douglas Laird, Xiangnan Du, et al. Alterations Impacting the PI3K PathwayXL765 (SAR245709) in Tumor Models with Diverse Genetic Characterization of the Activity of the PI3K/mTOR Inhibitor
Updated version
10.1158/1535-7163.MCT-13-0709doi:
Access the most recent version of this article at:
Material
Supplementary
http://mct.aacrjournals.org/content/suppl/2014/03/14/1535-7163.MCT-13-0709.DC1
Access the most recent supplemental material at:
Manuscript
Authoredited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
.pubs@aacr.orgDepartment at
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://mct.aacrjournals.org/content/early/2014/03/14/1535-7163.MCT-13-0709To request permission to re-use all or part of this article, use this link
on July 13, 2018. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on March 14, 2014; DOI: 10.1158/1535-7163.MCT-13-0709